In Brief: Cardiac Pathways Corp.
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pathways Corp.: Receives investigational device exemption from FDA for its Arrhythmia Mapping System, a cardiac ablation system that utilizes a 64-electrode mapping "basket" catheter to "diagnose and treat patients with complex tachyarrhythmias." The Sunnyvale, California-based company says it will begin a multicentered feasibility study of the system within two weeks at Brigham & Women's Hospital in Boston and St. Mary's Hospital in Rochester, Minnesota. The study will make privately held Cardiac Pathways "the first company to begin clinical trials of an integrated mapping system in the left ventricle," according to the firm...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.